Blog
RSS FeedPosted by Michael Wonder on 31 May 2021
Campaign launched for life-sustaining treatment access across Canada
31 May 2021 - Alpha-1 Canada publicly launched Access for Alphas today, a campaign aimed at raising the awareness of alfa-1 ...
Posted by Michael Wonder on 25 May 2021
Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis
25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis. ...
Posted by Michael Wonder on 18 May 2021
Quebec announces intention to implement a biosimilar switching policy
18 May 2021 - Biosimilars Canada today congratulated the Government of Quebec and Minister of Health and Social Services Christian ...
Posted by Michael Wonder on 18 May 2021
Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars
18 May 2021 - The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta ...
Posted by Michael Wonder on 17 May 2021
Sandoz Canada launches its 6th biosimilar with Inclunox and Inclunox HP (enoxaparin sodium solution for injection 100 mg/mL and 150 mg/mL (high potency))
17 May 2021 - New Sandoz biosimilar launch can potentially lower healthcare costs, especially for Canadian hospitals, as 75% of the ...
Posted by Michael Wonder on 13 May 2021
Long waits for life saving drugs harming Canadians: report
13 May 2021 - Canadians wait 15 months longer on average for new and potentially life-saving medications compared to Americans ...
Posted by Michael Wonder on 11 May 2021
Alberta faces shortage of COVID-19 drug as global demand spikes
11 May 2021 - Provinces with highest case rates hit by shortage of medication for sickest patients. ...
Posted by Michael Wonder on 06 May 2021
Alberta, Canada, begins mandating switches from originator to biosimilar Humira
6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...
Posted by Michael Wonder on 05 May 2021
Canadian agency recommends Ruzurgi be reimbursed with conditions
5 May 2021 - CADTH has recommended that Ruzurgi (amifampridine) be reimbursed for the treatment of Lambert-Eaton myasthenic syndrome in ...
Posted by Michael Wonder on 29 Apr 2021
Bavencio receives reimbursement recommendation from pCODR and INESSS for the maintenance treatment of patients with advanced bladder cancer
29 April 2021 - EMD Serono Canada and Pfizer Canada are pleased to announce that Bavencio (avelumab for injection) has received ...
Posted by Michael Wonder on 29 Apr 2021
Valeo Pharma’s Redesca and Redesca HP to be covered under the Ontario Public Drug Benefit Program
28 April 2021 - Additional provincial coverage expected to follow. ...
Posted by Michael Wonder on 29 Apr 2021
Integration of ethical considerations into HTA reports: an analysis of integration levels using a systematic review
26 April 2021 - The objective was to describe the type and level of ethical integration in published health technology assessment ...
Posted by Michael Wonder on 27 Apr 2021
‘Demand is outstripping the supply’: Is Canada running out of AstraZeneca COVID-19 vaccines?
26 April 2021- Canada’s National Advisory Committee on Immunizations says the AstraZeneca COVID-19 vaccine can now be offered to people ...
Posted by Michael Wonder on 22 Apr 2021
New Brunswick becomes third province in Canada to implement biosimilar switching policy
21 April 2021 - Biosimilars Canada today congratulated the Government of New Brunswick for implementing a biosimilar "switching" or transitioning ...
Posted by Michael Wonder on 19 Apr 2021
Canada confirms second blood clot case linked to AstraZeneca coronavirus vaccine, but it will be used to battle third wave
19 April 2021 - Canada has reported a second case of rare blood clots linked to the AstraZeneca COVID-19 vaccine in ...